Skip to main content
. 2018 Nov 14;60:e72. doi: 10.1590/S1678-9946201860072

Table 1. Socio-demographic and clinical variables of the study population.

Parameter Total patients (n=56)
Gender, n (%)
Male 37 (66%)
Female 19 (34%)
Mean age (SD) years 57.4 ± 11.4
Treatment received
SOF + DAC ± RBV 38 (67.8%)
SOF + SMV ± RBV 17 (30.3%)
SOF + RBV 1 (1.7%)
Time since diagnosis, years (SD) 10.87 ± 9.67
Genotype
1 42 (75%)
2 1 (1.7%)
3 13 (23.2%)
Treatment duration
12 w 44 (78.5%)
24 w 12 (21.5%)
Metavir
NI 15 (26.7%)
F2 9 (16%)
F3 15 (26.7%)
F4 17 (30.3%)
Patients previously treated 35 (62%)
Viral load ≥ 800.000 IU mL-1 27 (48%)
Race
White 41 (73.2%)
Black 5 (9%)
Others 10 (17%)
Marital status
Married 31 (55%)
Single 10 (17.8%)
Separated 10 (17.8%)
Widowed 5 (9%)
Educational level
Illiterate 1 (1.7%)
Elementary school 8 (14.2%)
Secondary school 29 (51%)
High school 18 (32%)
Patients with other comorbidities 33 (59%)
Patients with addictions 16 (28%)

Abbreviations: NI: not informed; RBV: ribavirin; SOF: sofosbuvir; SMV: simeprevir